Literature DB >> 31095444

PARP3 comes to light as a prime target in cancer therapy.

José Manuel Rodriguez-Vargas1, Léonel Nguekeu-Zebaze1, Françoise Dantzer1.   

Abstract

Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyze a post-translational modification of proteins to promote, control or adjust numerous cellular events including genome integrity, transcription, differentiation, cell metabolism or cell death. In the late years, PARP3 has been specified for its primary functions in programmed and stress-induced double-strand break repair, chromosomal rearrangements, transcriptional regulation in the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition awaits additional investigations. In this review, we discuss the newest advancements on the specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective inhibition for cancer therapy.

Entities:  

Keywords:  Poly(ADP-ribose) polymerase 3/EMT/mTORC2; cancer aggressiveness

Year:  2019        PMID: 31095444      PMCID: PMC6592235          DOI: 10.1080/15384101.2019.1617454

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  44 in total

1.  Involvement of mTOR signaling pathways in regulating growth and dissemination of metastatic brain tumors via EMT.

Authors:  Amanda Kwasnicki; Dhruve Jeevan; Alex Braun; Raj Murali; Meena Jhanwar-Uniyal
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

Review 3.  mTOR signaling at a glance.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  J Cell Sci       Date:  2009-10-15       Impact factor: 5.285

4.  PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3.

Authors:  Anders E G Lindgren; Tobias Karlberg; Ann-Gerd Thorsell; Mareike Hesse; Sara Spjut; Torun Ekblad; C David Andersson; Ana Filipa Pinto; Johan Weigelt; Michael O Hottiger; Anna Linusson; Mikael Elofsson; Herwig Schüler
Journal:  ACS Chem Biol       Date:  2013-06-25       Impact factor: 5.100

Review 5.  Exploring and comparing adverse events between PARP inhibitors.

Authors:  Christopher J LaFargue; Graziela Z Dal Molin; Anil K Sood; Robert L Coleman
Journal:  Lancet Oncol       Date:  2019-01       Impact factor: 41.316

6.  Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.

Authors:  Minghai Shao; Liyun Cao; Changyu Shen; Minati Satpathy; Bhadrani Chelladurai; Robert M Bigsby; Harikrishna Nakshatri; Daniela Matei
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 7.  PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes.

Authors:  Rebecca Gupte; Ziying Liu; W Lee Kraus
Journal:  Genes Dev       Date:  2017-01-15       Impact factor: 11.361

8.  Dna is a New Target of Parp3.

Authors:  E A Belousova; А A Ishchenko; O I Lavrik
Journal:  Sci Rep       Date:  2018-03-08       Impact factor: 4.379

9.  PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways.

Authors:  Carole Beck; Christian Boehler; Josée Guirouilh Barbat; Marie-Elise Bonnet; Giuditta Illuzzi; Philippe Ronde; Laurent R Gauthier; Najat Magroun; Anbazhagan Rajendran; Bernard S Lopez; Ralph Scully; François D Boussin; Valérie Schreiber; Françoise Dantzer
Journal:  Nucleic Acids Res       Date:  2014-03-05       Impact factor: 16.971

10.  PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.

Authors:  Olga Karicheva; José Manuel Rodriguez-Vargas; Nadège Wadier; Kathline Martin-Hernandez; Romain Vauchelles; Najat Magroun; Agnès Tissier; Valérie Schreiber; Françoise Dantzer
Journal:  Oncotarget       Date:  2016-09-27
View more
  10 in total

Review 1.  Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Authors:  Benedikt Heitmeir; Miriam Deniz; Wolfgang Janni; Brigitte Rack; Fabienne Schochter; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

2.  Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis.

Authors:  Ohoud Subhi; Hans-Juergen Schulten; Nadia Bagatian; Roa'a Al-Dayini; Sajjad Karim; Sherin Bakhashab; Reem Alotibi; Alaa Al-Ahmadi; Manar Ata; Aisha Elaimi; Saad Al-Muhayawi; Majid Mansouri; Khalid Al-Ghamdi; Osman Abdel Hamour; Awatif Jamal; Jaudah Al-Maghrabi; Mohammed Hussain Al-Qahtani
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

3.  Recurrent chromosome reshuffling and the evolution of neo-sex chromosomes in parrots.

Authors:  Zhen Huang; Ivanete De O Furo; Jing Liu; Valentina Peona; Anderson J B Gomes; Wan Cen; Hao Huang; Yanding Zhang; Duo Chen; Ting Xue; Qiujin Zhang; Zhicao Yue; Quanxi Wang; Lingyu Yu; Youling Chen; Alexander Suh; Edivaldo H C de Oliveira; Luohao Xu
Journal:  Nat Commun       Date:  2022-02-17       Impact factor: 17.694

Review 4.  Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.

Authors:  Iain A Richard; Joshua T Burgess; Kenneth J O'Byrne; Emma Bolderson
Journal:  Front Cell Dev Biol       Date:  2022-01-14

5.  PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells.

Authors:  Leonel Nguekeu-Zebaze; Najat Hanini; Aurélia Noll; Nadège Wadier; Jean-Christophe Amé; Lisa Roegel; Françoise Dantzer
Journal:  Sci Rep       Date:  2022-09-15       Impact factor: 4.996

6.  Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors.

Authors:  Xuwei Shao; Steven Pak; Uday Kiran Velagapudi; Shruthi Gobbooru; Sai Shilpa Kommaraju; Woon-Kai Low; Gopal Subramaniam; Sanjai Kumar Pathak; Tanaji T Talele
Journal:  Bioorg Chem       Date:  2020-07-08       Impact factor: 5.307

Review 7.  The Controversial Roles of ADP-Ribosyl Hydrolases MACROD1, MACROD2 and TARG1 in Carcinogenesis.

Authors:  Karla L H Feijs; Christopher D O Cooper; Roko Žaja
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

8.  Identifying Blood Transcriptome Biomarkers of Alzheimer's Disease Using Transgenic Mice.

Authors:  Shinichiro Ochi; Jun-Ichi Iga; Yu Funahashi; Yuta Yoshino; Kiyohiro Yamazaki; Hiroshi Kumon; Hiroaki Mori; Yuki Ozaki; Takaaki Mori; Shu-Ichi Ueno
Journal:  Mol Neurobiol       Date:  2020-08-20       Impact factor: 5.590

9.  Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair-Related Genes.

Authors:  Dai Zhang; Si Yang; Yiche Li; Jia Yao; Jian Ruan; Yi Zheng; Yujiao Deng; Na Li; Bajin Wei; Ying Wu; Zhen Zhai; Jun Lyu; Zhijun Dai
Journal:  JAMA Netw Open       Date:  2020-10-01

Review 10.  Uncovering the Invisible: Mono-ADP-ribosylation Moved into the Spotlight.

Authors:  Ann-Katrin Hopp; Michael O Hottiger
Journal:  Cells       Date:  2021-03-19       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.